GRI signs exclusive distribution deal

Published: 15-Mar-2004


GRI (Genetic Research Instrumentation), the UK supplier of biotechnology products, has signed an exclusive distribution agreement with Agencourt Biosciences Corporation. The agreement permits GRI to market Agencourt's innovative Solid Phase Reversible Immobilisation (SPRI) technology within the UK, Irish and French scientific communities. Agencourt Bioscience Corporation is a provider of nucleic acid purification products and it offers an array of SPRI-based nucleic acid purification kits for customers who wish to improve and automate their own sequencing and discovery initiatives. SPRI is a patented, high performance purification technology based on the selective immobilisation of nucleic acids onto magnetic microparticles. SPRI allows for easy automation of nucleic acid purification without sacrificing superior performance. Since its development, SPRI has been adopted by many of the largest genome research facilities, and to date has the largest validation set of any nucleic acid purification technology. The complete Agencourt SPRI range of products is available immediately from GRI's BioEssentials sales division.

T: +44 (0)1376 332900 simonn@gri.co.uk

You may also like